logo

Biohaven Pharmaceutical Holding Co Ltd. (BHVN)



Trade BHVN now with
  Date
  Headline
2/19/2019 7:32:42 AM Biohaven' Verdiperstat Gets Orphan Drug Designation From FDA For Multiple System Atrophy
2/4/2019 7:36:50 AM Biohaven Says Administration Of Intranasal BHV-3500 In Phase 1 Trial Achieved Targeted Therapeutic Exposures
1/23/2019 3:01:02 AM Biohaven Gets FDA May Proceed Letter For Phase 3 Clinical Trial Of BHV-3241 For Multiple System Atrophy
1/7/2019 3:00:46 AM Biohaven Announces Acceptance Of IND Filing For Rimegepant In China
12/12/2018 10:59:11 PM Biohaven Announces Pricing Of Its Offering Of 3.36 Mln Shares At $37.25/shr
12/10/2018 7:48:09 PM Biohaven Pharma Commences Underwritten Public Offering Of 3 Mln Of Its Common Shares
12/10/2018 3:04:18 AM Biohaven Announces Positive Results From Rimegepant Long-Term Safety Study
12/3/2018 3:02:33 AM Biohaven Pharma Reports Positive Topline Results From Phase 3 Clinical Trial Zydis ODT Formulation Of Rimegepant
11/26/2018 3:04:04 AM Biohaven Announces FDA Acceptance Of 505(b)(2) NDA Filing For BHV-0223
11/15/2018 7:41:30 AM William Blair Is Lowering Biohaven Pharmaceutical Holding Co Ltd. (BHVN) FY19 Estimate To -6.51 From -5.54
11/15/2018 7:41:14 AM William Blair Is Lowering Biohaven Pharmaceutical Holding Co Ltd. (BHVN) FY18 Estimate To -6.58 From -5.75
11/15/2018 7:40:27 AM William Blair Reiterates Biohaven Pharmaceutical Holding Co Ltd. (BHVN) At Outperform
11/15/2018 3:01:57 AM Biohaven Reports Enrolling First Patient In Phase 3 Preventive Treatment Of Migraine Trial
11/14/2018 3:15:56 AM Biohaven Pharma Q3 Loss Attributable To Common Shareholders $61.4 Mln Or $1.53/Shr Vs $42.9 Mln Or $1.19/Shr Last Year
10/22/2018 3:13:50 AM Biohaven Gets Authorization To Proceed From FDA And Doses First Subject With BHV-3500
10/9/2018 3:01:47 AM Biohaven Pharma Inks Deal With University Of Connecticut For Development And Commercialization Rights To UC1MT
9/12/2018 6:21:11 AM Biohaven Submits IND For BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist For Treatment Of Migraine
9/12/2018 3:01:05 AM Biohaven Appoints Bob Repella To Board
  
 
>